TRIP6 and ovarian carcinoma: Nonetheless, depletion of TRIP6 by either shRNA (Figure 3h) or Cas9/sgRNA (Figure 3i) not only enhanced the association of TRAF6 with A20, but also with CYLD in untreated and treated cells, suggesting a significant role for TRIP6 in antagonizing the binding of TRAF6 to both A20 and CYLD in ovarian cancer cells.